Entering text into the input field will update the search result below

Inhibrx's INBRX-101 for AAT deficiency gets FDA's orphan drug designation

Mar. 03, 2022 9:45 AM ETInhibrx, Inc. (INBX)By: Ravikash, SA News Editor

Headquarters of US Food and Drug Administration (FDA)

Grandbrothers/iStock Editorial via Getty Images

  • The U.S. Food and Drug Administration granted orphan drug designation to Inhibrx's (INBX) INBRX-101 to treat alpha-1 antitrypsin deficiency, or AATD.
  • AATD is an inherited disease characterized by deficient levels of the AAT protein, which causes

Recommended For You


Have a tip? Submit confidentially to our News team. Found a factual error? Report here.

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.